XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2022
Jan. 31, 2021
Apr. 30, 2021
Cash flows from operating activities:          
Net loss $ (5,471) $ (3,151) $ (13,721) $ (9,560) $ (14,800)
Adjustments to reconcile net loss to net cash used in operating activities:          
Foreign exchange loss (gain) (5) (3) (13)  
Depreciation of fixed assets     104 106  
Amortization of intangible assets     18  
Amortization of right of use asset     211 159  
Loss on disposal of property, plant and equipment     2  
Gain on extinguishment of PPP Loan (890)  
Stock-based compensation 317 115 864 338  
Change in fair value of contingent liability     (60)  
Changes in operating assets and liabilities, net of acquisition:          
Accounts receivable     237 105  
Contract assets     (217) 188  
Inventory     (193)  
Other assets     51 (310)  
Accounts payable     (165) (473)  
Accrued expenses     (589) 1,192  
Change in lease liability     (228) (169)  
Contract liabilities     15 (90)  
Litigation payable     (1,224)  
Net cash used in operating activities     (15,787) (8,525) (11,700)
Cash flows from investing activities:          
Purchase of property, plant and equipment     (319) (17)  
Payments for MAR acquisition, net of cash acquired     (3,544)  
Net cash used in investing activities     (3,863) (17)  
Cash flows from financing activities:          
Proceeds from Paycheck Protection Program Loan     890  
Proceeds from loan payable     467  
Payments of loan payable     (292)  
Proceeds from stock option exercises     90 40  
Proceeds from issuance of common stock- Aspire financing net of issuance costs     9,983  
Proceeds from issuance of common stock- AGP At The Market offering, net of issuance costs     66,166  
Proceeds associated with exercise of common stock warrants     769  
Acquisition of treasury stock     (36)  
Net cash provided by financing activities     90 77,987  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (14) 32  
Net (decrease) / increase in cash, cash equivalents and restricted cash     (19,574) 69,477  
Cash, cash equivalents and restricted cash, beginning of period     83,634 10,930 10,930
Cash, cash equivalents and restricted cash, end of period $ 64,060 $ 80,407 64,060 80,407 $ 83,634
Supplemental disclosure of noncash operating activities:          
Prepaid financing costs reported in accrued expenses     62  
Supplemental disclosure of noncash investing and financing activities:          
Acquisition of property, plant and equipment through accounts payable     9  
Issuance of common stock in acquisition of MAR     5,855  
Advance payable – MAR     456  
Contingent liability     1,591  
Outstanding receivable for sale of shares from warrant exercises     1,838  
Outstanding receivable for sale of shares from stock option exercises     $ 144